376 related articles for article (PubMed ID: 32772383)
1. Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial.
Anton RF; Voronin KE; Book SW; Latham PK; Randall PK; Glen WB; Hoffman M; Schacht JP
Alcohol Clin Exp Res; 2020 Oct; 44(10):2084-2096. PubMed ID: 32772383
[TBL] [Abstract][Full Text] [Related]
2. Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes.
Anton RF; Voronin KK; Randall PK; Myrick H; Tiffany A
Alcohol Clin Exp Res; 2012 Nov; 36(11):2000-7. PubMed ID: 22551036
[TBL] [Abstract][Full Text] [Related]
3. [A pharmacogenetic analysis of dopaminergic and opioidergic genes in opioid addicts treated with the combination of naltrexone and guanfacine].
Kibitov АО; Krupitsky ЕМ; Blokhina ЕА; Verbitskaya ЕV; Brodyansky VМ; Alekseeva NP; Bushara NМ; Yaroslavtseva ТS; Palatkin VY; Masalov DV; Burakov АМ; Romanova ТN; Sulimov GY; Grinenko AY; Kosten Т; Nielsen D; Zvartau EE
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(11. Vyp. 2):36-48. PubMed ID: 28300812
[TBL] [Abstract][Full Text] [Related]
4. Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues.
Schacht JP; Anton RF; Voronin KE; Randall PK; Li X; Henderson S; Myrick H
Neuropsychopharmacology; 2013 Feb; 38(3):414-22. PubMed ID: 23032071
[TBL] [Abstract][Full Text] [Related]
5. Interactive effects of OPRM1 and DAT1 genetic variation on subjective responses to alcohol.
Ray LA; Bujarski S; Squeglia LM; Ashenhurst JR; Anton RF
Alcohol Alcohol; 2014; 49(3):261-70. PubMed ID: 24421289
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphisms of DAT1 and COMT differentially associate with actigraphy-derived sleep-wake cycles in young adults.
Valomon A; Holst SC; Bachmann V; Viola AU; Schmidt C; Zürcher J; Berger W; Cajochen C; Landolt HP
Chronobiol Int; 2014 Jun; 31(5):705-14. PubMed ID: 24625311
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in Alcohol Use Disorder: a randomized trial.
Schacht JP; Hoffman M; Chen BH; Anton RF
Pharmacogenomics J; 2022 Feb; 22(1):1-8. PubMed ID: 34381173
[TBL] [Abstract][Full Text] [Related]
8. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.
Anton RF; Oroszi G; O'Malley S; Couper D; Swift R; Pettinati H; Goldman D
Arch Gen Psychiatry; 2008 Feb; 65(2):135-44. PubMed ID: 18250251
[TBL] [Abstract][Full Text] [Related]
9. Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder.
Hartwell EE; Feinn R; Morris PE; Gelernter J; Krystal J; Arias AJ; Hoffman M; Petrakis I; Gueorguieva R; Schacht JP; Oslin D; Anton RF; Kranzler HR
Addiction; 2020 Aug; 115(8):1426-1437. PubMed ID: 31961981
[TBL] [Abstract][Full Text] [Related]
10. Dopaminergic Genetic Variation Influences Aripiprazole Effects on Alcohol Self-Administration and the Neural Response to Alcohol Cues in a Randomized Trial.
Schacht JP; Voronin KE; Randall PK; Anton RF
Neuropsychopharmacology; 2018 May; 43(6):1247-1256. PubMed ID: 29362512
[TBL] [Abstract][Full Text] [Related]
11. The effect of OPRM1 and COMT genotypes on the analgesic response to intravenous fentanyl labor analgesia.
Landau R; Liu SK; Blouin JL; Carvalho B
Anesth Analg; 2013 Feb; 116(2):386-91. PubMed ID: 23302985
[TBL] [Abstract][Full Text] [Related]
12. The opioid receptor mu 1 (OPRM1) rs1799971 and catechol-O-methyltransferase (COMT) rs4680 as genetic markers for placebo analgesia.
Aslaksen PM; Forsberg JT; Gjerstad J
Pain; 2018 Dec; 159(12):2585-2592. PubMed ID: 30130297
[TBL] [Abstract][Full Text] [Related]
13. OPRM1 rs1799971, COMT rs4680, and FAAH rs324420 genes interact with placebo procedures to induce hypoalgesia.
Colloca L; Wang Y; Martinez PE; Chang YC; Ryan KA; Hodgkinson C; Goldman D; Dorsey SG
Pain; 2019 Aug; 160(8):1824-1834. PubMed ID: 31335650
[TBL] [Abstract][Full Text] [Related]
14. Independent and Interactive Effects of OPRM1 and DAT1 Polymorphisms on Alcohol Consumption and Subjective Responses in Social Drinkers.
Weerts EM; Wand GS; Maher B; Xu X; Stephens MA; Yang X; McCaul ME
Alcohol Clin Exp Res; 2017 Jun; 41(6):1093-1104. PubMed ID: 28376280
[TBL] [Abstract][Full Text] [Related]
15. Cloninger's temperament and character dimensions and dopaminergic genes: DAT1 VNTR and COMT Val158Met polymorphisms.
Glavina Jelaš I; Dević I; Karlović D
Psychiatr Danub; 2018 Mar; 30(1):47-56. PubMed ID: 29546858
[TBL] [Abstract][Full Text] [Related]
16. Topiramate Versus Naltrexone for Alcohol Use Disorder: A Genotype-Stratified Double-Blind Randomized Controlled Trial.
Morley KC; Kranzler HR; Luquin N; Jamshidi N; Adams C; Montebello M; Tremonti C; Dali G; Logge W; Baillie A; Teesson M; Trent R; Haber PS
Am J Psychiatry; 2024 May; 181(5):403-411. PubMed ID: 38706338
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans.
Arias AJ; Gelernter J; Gueorguieva R; Ralevski E; Petrakis IL
Am J Addict; 2014; 23(3):288-93. PubMed ID: 24724887
[TBL] [Abstract][Full Text] [Related]
18. Variation in genes involved in dopamine clearance influence the startle response in older adults.
Armbruster D; Mueller A; Strobel A; Lesch KP; Kirschbaum C; Brocke B
J Neural Transm (Vienna); 2011 Sep; 118(9):1281-92. PubMed ID: 21445667
[TBL] [Abstract][Full Text] [Related]
19. Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status.
Schacht JP; Randall PK; Latham PK; Voronin KE; Book SW; Myrick H; Anton RF
Neuropsychopharmacology; 2017 Dec; 42(13):2640-2653. PubMed ID: 28409564
[TBL] [Abstract][Full Text] [Related]
20. Effects of pharmacological and genetic regulation of COMT activity in alcohol use disorder: a randomized, placebo-controlled trial of tolcapone.
Schacht JP; Yeongbin Im ; Hoffman M; Voronin KE; Book SW; Anton RF
Neuropsychopharmacology; 2022 Oct; 47(11):1953-1960. PubMed ID: 35523943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
